Analytical Data
-
Gene name
SIGMAR1
- Application
-
Alternative Names
OPRS1; SRBP
-
Species
Human
-
Source
Baculovirus
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99720-1
-
Expression Region
M1-P223
-
Protein Length
Full Length of Isoform-1
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SIGMAR1, or sigma receptor 1, has emerged as a significant focus of research due to its pivotal role in various neurobiological processes and its potential implications in treating neurological disorders. Initially identified as a receptor involved in the regulation of cell survival and neuroprotection, SIGMAR1 is located primarily in the endoplasmic reticulum and plays a critical role in modulating calcium signaling and mitochondrial function. Research has shown that SIGMAR1 interacts with several proteins, influencing neuroplasticity, stress responses, and apoptosis pathways. Its involvement in diseases such as Alzheimer's, Parkinson's, and schizophrenia highlights the therapeutic potential of targeting this receptor. Recent studies have also indicated that SIGMAR1 may facilitate neuroprotective effects against excitotoxicity and inflammation, making it a promising candidate for drug development. Furthermore, the exploration of SIGMAR1 as a biomarker for various neurodegenerative conditions adds another layer of significance to its study. The development and characterization of SIGMAR1 recombinant proteins have paved the way for a deeper understanding of its structure-function relationship and may aid in the identification of novel therapeutic agents that can modulate its activity for clinical benefit. Overall, the ongoing research into SIGMAR1 not only illuminates its crucial functions within the nervous system but also opens avenues for innovative treatments for a range of debilitating neurological disorders.
